Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock
Vir Biotechnology (VIR) priced a public offering of 15M shares at $10 each, raising $150M. Underwriters have a 30-day option for 2.25M more shares. Closing is expected November 16, 2026. Latham & Watkins advised the underwriters.
How this was made
The 30-second read
Why it matters
The $150 M raise provides capital for pipeline advancement but introduces dilution, likely prompting a near‑term price dip.
Market read
Primary disclosure of a mid‑size biotech equity raise; relevant for short‑term traders and sector investors.
What to watch
Potential strategic partnership or pipeline milestones that could be financed by the proceeds.
Background
Vir Biotechnology is a clinical‑stage biopharma focused on infectious diseases and cancer. The offering is underwritten and includes an over‑allotment option.
Ticker impact
Vir Biotechnology announced pricing of a $150 million public offering of 15 M shares at $10 each, with a 30‑day option for 2.25 M additional shares.
likely pressure as the market prices in dilution from the $150 M capital raise
First report of a sizable primary offering; investors typically react with short‑term sell pressure.
Market effects
Adds supply to the biotech financing market, may prompt peers to reassess fundraising timing.
US biotech sector could see modest short‑term weakness.
Limited to investors focused on biotech equities and capital‑raising activity.
Counterpoint
If the raise funds a breakthrough trial, the long‑term upside could outweigh short‑term dilution concerns.
Key entities
- companyVir Biotechnology, Inc.
Issuer of the public offering.
- law_firmLatham & Watkins LLP
Advised the underwriters on the transaction.


